BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo^® (Cemiplimab) Combination in NSCLC

BioNTech SE announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo®, a PD-1 inhibitor, in advanced non-small cell lung cancer.